Section of Anatomic Pathology, Azienda Ospedaliera Universitaria "Gaetano Martino" and Department of Human Pathology "Gaetano Barresi", University of Messina, 98123 Messina, Italy.
Dis Markers. 2018 Feb 18;2018:1505428. doi: 10.1155/2018/1505428. eCollection 2018.
A cribriform architectural pattern has been reported in 9% of one unselected consecutively collected series of gastric carcinomas (GC) with unfavourable prognostic outcome. Taking into consideration the biological relevance of the human epidermal growth factor receptor 2 (HER2) status, we have analyzed a cohort of GC with a cribriform component more than 40% (CGC) to evaluate the HER2 amplification rate as a potential target for therapy with trastuzumab.
HER2 overexpression was encountered in 21 of 100 (21%) GC; a progressive increase in HER2 amplification was appreciated moving from non-CGC (20.6%) towards CGC cases (21.6%), although this difference does not reach a statistical significance. Nevertheless, either in univariate or in multivariate analyses, stage and HER2 status showed a significant value (<0.001) in CGC patients.
Our data confirmed a worse prognosis in all CGC patients with HER2 amplification, resulting in a shorter survival time. We invite all pathologists in their daily practice to specify the occurrence of cribriform neoplastic component in GC, either in surgical or in bioptical samples, taking into practical assessment the high HER2 overexpression rate in order to correctly treat these patients with worse behavior.
在一项未选择的连续收集的胃癌（GC）系列中，有 9%的病例报道存在筛状结构模式，且预后不良。考虑到人类表皮生长因子受体 2（HER2）状态的生物学相关性，我们分析了一组具有>40%筛状成分的 GC（CGC），以评估 HER2 扩增率作为曲妥珠单抗治疗的潜在靶点。
在 100 例 GC 中，有 21 例（21%）存在 HER2 过表达；从非 CGC（20.6%）到 CGC 病例（21.6%），HER2 扩增逐渐增加，尽管这种差异没有达到统计学意义。然而，无论是在单因素还是多因素分析中，分期和 HER2 状态在 CGC 患者中均具有显著的 值（<0.001）。
我们的数据证实了所有 CGC 患者中 HER2 扩增的预后更差，导致生存时间更短。我们邀请所有病理学家在日常实践中，无论是在手术还是生物样本中，都要明确指出 GC 中筛状肿瘤成分的发生，并考虑到高 HER2 过表达率进行实际评估，以便正确治疗这些行为较差的患者。
